Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Mustang Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
MBIO
Nasdaq
8731
https://www.mustangbio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Mustang Bio Inc
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
- Mar 28th, 2024 1:00 pm
Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate Highlights
- Mar 11th, 2024 8:05 pm
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
- Mar 7th, 2024 12:30 pm
Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology Conference
- Jan 11th, 2024 1:30 pm
Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual Meeting
- Dec 11th, 2023 1:30 pm
Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
- Nov 14th, 2023 9:05 pm
Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual Meeting
- Nov 2nd, 2023 1:28 pm
Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Oct 30th, 2023 6:15 pm
Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
- Oct 26th, 2023 4:30 pm
Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma
- Oct 26th, 2023 1:00 pm
Mustang Bio to Participate in Upcoming September 2023 Investor Conferences
- Sep 7th, 2023 12:15 pm
Mustang Bio Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy
- Aug 16th, 2023 12:00 pm
Mustang Bio Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- Aug 14th, 2023 8:05 pm
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
- Aug 14th, 2023 8:01 pm
Mustang Bio to Participate in Two August 2023 Investor Conferences
- Aug 3rd, 2023 12:00 pm
Mustang Bio Announces Amendment and Closing of Strategic Manufacturing Partnership Transaction with uBriGene (Boston) Biosciences
- Jul 31st, 2023 12:30 pm
Mustang Bio Announces Participation in Upcoming Scientific Meetings
- Jul 6th, 2023 12:00 pm
Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy
- Jun 15th, 2023 8:01 pm
Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data
- Jun 13th, 2023 5:49 pm
Wall Street Analysts Think Mustang Bio, Inc. (MBIO) Could Surge 331.15%: Read This Before Placing a Bet
- Jun 12th, 2023 1:55 pm
Scroll